https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
nter, collaborative testing, for example, network trials. In the absence of a proven cerebroprotective agent to use as a gold standard, however, it remains speculative whether such comprehensive preclinical assessment can effectively predict clinical outcome.Aim This study assessed the utility of osteopontin (OPN) and galectin-3 (Gal-3) as biomarkers of maladaptive right ventricular remodeling in pulmonary hypertension (PH). Materials methods We examined plasma levels of OPN and Gal-3 in patients with PH (n = 62), dil
Aimer
Commentaire
Partagez
